Exhibit 99.1
THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.
If you are in any doubt as to any aspect of the proposals referred to in this notice or as to the action you should take, please take advice from a
stockbroker, solicitor, accountant or other independent professional adviser.
If you have sold or otherwise transferred all of your ordinary shares
in the capital of the Company (Ordinary Shares), please send this document, together with the enclosed documents, at once to the purchaser or transferee, or to the stockbroker, bank or other agent through whom the sale or transfer
was effected for transmission to the purchaser or transferee.
It is important that you submit your proxy vote electronically. Proxies may be
submitted electronically using Link Groups Signal Shares share portal service at www.signalshares.com or in hard copy form if you request a hard copy Form of Proxy from the Companys registrar, Link Group. In order to be valid, proxy
appointments must be submitted using Link Groups Signal Shares share portal service or in hard copy form to Link Group at PXS 1, Central Square, 29 Wellington Street, Leeds LS1 4DL, in each case, so as to be received by no later than 2.00 p.m.
(UK Time) on 14 December 2023 or 48 hours before any adjourned meeting. The electronic appointment of a proxy using Link Groups Signal Shares share portal service or the completion and return of a Form of Proxy in hard copy form will not
preclude shareholders from attending and voting at the General Meeting should they so wish. Any hard copy Form of Proxy should, to be valid, be completed and signed in accordance with the instructions printed on it.
If you require a hard copy Form of Proxy (or assistance with how to complete, sign and return it) or assistance in submitting your proxy appointment
electronically, please call Link Groups portal team on +44 (0)371 664 0391. Calls are charged at the standard geographic rate and will vary by provider. Calls from outside the UK will be charged at the applicable international rate. Lines are
open 9.00 a.m. to 5.30 p.m. (UK Time), Monday to Friday, excluding public holidays in England and Wales.
If you hold your Ordinary Shares in
uncertificated form (i.e. in CREST), you may appoint a proxy for the General Meeting by completing and transmitting a CREST Proxy Instruction in accordance with the procedures set out in the CREST Manual issued by Euroclear so that it is received by
the registrar (under CREST Participation ID RA10) by no later than 2.00 p.m. (UK Time) on 14 December 2023. The time of receipt will be taken to be the time from which the registrar is able to retrieve the message by enquiry to CREST in the
manner proscribed by CREST.
A copy of this document will also be available on the Companys website, https://www.mereobiopharma.com/gm2023
NOTICE OF THE GENERAL MEETING OF
MEREO BIOPHARMA GROUP PLC
(THE
COMPANY)
to be held at the 5th Floor, One Cavendish Place, London W1G 0QF, United Kingdom
on 18 December 2023 at 2.00 p.m. (UK Time)
Cautionary note regarding forward-looking
statements
This document contains statements about the Company that are or may be forward-looking statements. We intend such
forward-looking statements to be covered by the safe harbour provisions for forward-looking statements contained in Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as
amended. All statements, other than statements of historical facts, included in this document, including, without limitation, statements regarding our status as a foreign private issuer and the consequences of losing such status are
forward-looking statements. The words targets, plans, believes, expects, aims, intends, will, may, should, anticipates,
estimates, projects or words or terms of similar substance, or the negative thereof, are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These
forward-looking statements are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause the actual results, performance or achievements of any such
person, or industry results, to differ materially from any results, performance